The covenant
The covenant is how we are built.
Your information is used to work for you, not against you.
The PV1RX covenant is a product rule, a contract rule, a corporate rule, and a data-architecture rule. It is not marketing language.
01
The pharmacy is the beneficiary, never the product.
Identifiable pharmacy data is used to provide the pharmacy's service. It is scoped to the pharmacy and controlled for that relationship. PV1RX does not sell identifiable pharmacy data.
PV1RX may retain normalized, deidentified observations needed to improve methodology, measure outcomes, and produce legitimate aggregate evidence. Those observations are never a backdoor to exposing an identifiable pharmacy.
02
The math is visible and reproducible.
Every economic number shown to a pharmacy must be traceable to its own source files, a stated cost basis, a methodology version, and deterministic code.
No model produces, adjusts, or invents an economic figure. No missing acquisition cost is silently filled with AWP, NADAC, or another benchmark. If data cannot support a calculation, PV1RX says so.
03
No conflicted money.
PV1RX accepts no revenue from PBMs, wholesalers, coupon networks, or other counterparties that could benefit from changing what a pharmacy sees.
There is no pay-to-rank, sponsor-controlled finding, sponsored recommendation, percentage of recovery, or commercial mechanism through which a finding can be altered, suppressed, or reordered.
04
Access widens as delivery cost falls.
The core Receipt is free forever. Paid work exists only where a person is still required for evidence review, exception handling, contract-term confirmation, or decision support.
As Ledger automates repeatable work, human minutes and delivery cost must decline. PV1RX's public-benefit obligation is to make access broader as the cost of delivery falls. Free is a consequence of automation and disciplined design, not a temporary promotion.
05
Evidence, not anecdote.
PV1RX records what it observed, what the pharmacy chose to do, and what changed afterward. It distinguishes observed amounts, potential actions, modeled opportunity, and realized value.
Aggregate evidence is an advocacy capability first. It is not the company's base financial model or a product built to monetize pharmacy data.
06
Neutral enough to outlive any partner.
No investor, sponsor, association, or institutional funder may control the methodology, findings, identifiable pharmacy data, or core access model.
PV1RX maintains direct pharmacy revenue at every stage. An association may underwrite member access but cannot own the database, determine the findings, or stop the company by discontinuing support.
Enforced in architecture
The covenant is written into the data model, not just the contract.
Fuller terms and data-processing details will be available before any paid engagement.
- 01Pharmacy-scoped identifiable data
- 02Separate deidentified observation store
- 03Minimum cell sizes for aggregate evidence
- 04No sponsor or rank field in findings
- 05Methodology version retained with results